Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| fixed dose prostaglandin combination |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| XALACOM | Drug | Xalacom eye drops |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency distribution of persistent and non-persistent patients across study cohorts | 12 months | |
| Frequency distribution of switchers, re-starters and discontinuing patients as well as patients commencing add-on therapy across the study cohorts | 12 months | |
| Time to discontinuation of each cohort | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Age and sex: Townsend Score of social deprivation, time since first THIN diagnosis of glaucoma or ocular hypertension | 12 months | |
| Procedures: Laser, Trabeculectomy, viscocanalostomy, deep sclerectomy | 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
patients who had received a prescription for either Xalacom, Ganfort and DuoTrav, > 18 years old, diagnosed with glaucoma or ocular hypertension, registered at the primary care practice for > 12 months
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
Not provided
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| Duotrav |
| Drug |
Duotrav eye drops |
|
| Ganfort | Drug | Ganfort eye drops |
|
| Ocular Pharmacological Treatments: Beta-blockers and Alpha-agonists | 12 months |
| Prostaglandin mono-therapies | 12 months |
| The cohort of patients which were evaluated in this study were investigated for the presence of history of disease for asthma, cardiovascular disease, diabetes, renal failure and systemic hypertension. The number of patients in each cohort were | 12 months |
| presented who had had (i) a 12 month history of any of the diseases or (ii) had had a history of any of the diseases. | 12 months |
| ID | Term |
|---|---|
| D005901 | Glaucoma |
| D009798 | Ocular Hypertension |
| ID | Term |
|---|---|
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C571753 | Xalacom |
| C571754 | Duotrav |
| C571755 | Ganfort |
Not provided
Not provided
Not provided